Pharmacokinetics and toxicity of weekly docetaxel in older patients.

Authors

• Arti Hurria
• Mark T Fleming
• Sharyn D Baker
• Wm Kevin Kelly
• Katie Cutchall
• Katherine Panageas
• James Caravelli
• Henry Yeung
• Mark G Kris
• Jorge Gomez
• Vincent A Miller
• Gabriella D'Andrea
• Howard I Scher
• Larry Norton
• Clifford Hudis

Publication/Presentation Date

10-15-2006

Abstract

PURPOSE: To evaluate the pharmacokinetics of weekly docetaxel in a cohort of older patients with metastatic cancer and to explore the relationship of pharmacokinetic variables, Erythromycin Breath Test results, age, geriatric assessment variables, and toxicity to therapy.

EXPERIMENTAL DESIGN: Twenty patients ages > or = 65 years with metastatic breast, prostate, or lung cancer entered an Institutional Review Board-approved protocol to evaluate the pharmacokinetics of weekly docetaxel administered at 35 mg/m2 i.v. for 3 weeks followed by a 1-week break. The Erythromycin Breath Test and geriatric assessment were done before the first dose. Blood samples were collected for pharmacokinetic analysis with the first dose of docetaxel.

RESULTS: Of the 20 patients who entered the study, 19 were evaluable. There were no age-related differences in the pharmacokinetics of weekly docetaxel. Fifty-eight percent (11 of 19) experienced grade > or = 3 toxicity: 16% (3 of 19) grade > or = 3 hematologic toxicity, and 53% (10 of 19) grade > or = 3 nonhematologic toxicity. There was an association between the Erythromycin Breath Test results and docetaxel pharmacokinetic variables; however, there was no association between Erythromycin Breath Test results or docetaxel pharmacokinetics with frequency of grade > or = 3 toxicity.

CONCLUSIONS: Despite no statistically significant age-related differences in weekly docetaxel pharmacokinetics, over half of these older patients experienced a grade > or = 3 toxicity at the 35 mg/m2 starting dose. We advocate a starting dose of 26 mg/m2 on this weekly schedule and dose escalating if no toxicity.

Volume

12

Issue

20 Pt 1

First Page

6100

Last Page

6105

ISSN

1078-0432

Published In/Presented At

Hurria, A., Fleming, M. T., Baker, S. D., Kelly, W. K., Cutchall, K., Panageas, K., Caravelli, J., Yeung, H., Kris, M. G., Gomez, J., Miller, V. A., D'Andrea, G., Scher, H. I., Norton, L., & Hudis, C. (2006). Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 12(20 Pt 1), 6100–6105. https://doi.org/10.1158/1078-0432.CCR-06-0200

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

17062686

Department(s)

Administration and Leadership

Document Type

Article